drugset
drugset / Trial / NCT01245803

Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS

NCT01245803 ↗

Phase 4 Unknown 400 enrolled Beijing Anzhen Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Rosuvastatin reload may prevent myocardial damage in ACS patients undergoing PCI

Timeline

Start
2010-04
Primary completion
2011-04
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 10 mg Oral

Indications

acute coronary syndrome